House Democrats Start Multiple Sclerosis Drug Price Probe
- Biogen, Sanofi, Roche among drugmakers who received letter
- Reps. Cummings, Welch ask questions about ‘shadow pricing’
This article is for subscribers only.
House Democrats have started what they called an “in-depth” investigation into the pricing of drugs for neurological condition multiple sclerosis, the latest attempt by U.S. politicians to pressure manufacturers to lower costs.
Seven drugmakers -- Biogen Inc., Sanofi, Novartis AG, Roche Holding AG, Bayer AG, Merck KGaA’s EMD Serono unit and Teva Pharmaceuticals Industries Ltd. -- received letters requesting information on pricing strategies from Elijah Cummings and Peter Welch, two representatives who sit on the House Committee on Oversight and Government Reform.